Neurocrine Biosciences Inc
NASDAQ:NBIX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
111.62
153.15
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc
Accounts Receivables
Neurocrine Biosciences Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
Accounts Receivables
$481.1m
|
CAGR 3-Years
43%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Receivables
$11.5B
|
CAGR 3-Years
7%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Receivables
$4.6B
|
CAGR 3-Years
0%
|
CAGR 5-Years
7%
|
CAGR 10-Years
5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Receivables
$7.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Receivables
$1.8B
|
CAGR 3-Years
17%
|
CAGR 5-Years
32%
|
CAGR 10-Years
31%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Receivables
$6.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
18%
|
CAGR 10-Years
21%
|
|
Neurocrine Biosciences Inc
Glance View
Neurocrine Biosciences Inc. is a biopharmaceutical company committed to improving the lives of those suffering from neurological and endocrine disorders. Founded in 1992 and based in San Diego, California, Neurocrine has carved out a niche in developing innovative therapies that target complex medical conditions. Its flagship product, Ingrezza (valbenazine), has rapidly gained traction as a leading treatment for tardive dyskinesia, a movement disorder often caused by long-term antipsychotic medication use. This success has propelled the company into the limelight and established it as a key player in the CNS (central nervous system) market. Investors are captivated by Neurocrine’s strong clinical pipeline, promising research partnerships, and an agile operational approach that enable it to adapt swiftly to the evolving landscape of biopharma. The company’s growth story is further enhanced by its commitment to expanding its product portfolio. With therapies in development for conditions such as endometriosis and other hormonal disorders, Neurocrine is not just a one-hit wonder; it is poised to become a powerhouse in the biotech domain. Boasting a robust financial position, the company leverages its research capabilities to identify and bring forward transformative treatments. For investors, Neurocrine represents an opportunity at the intersection of science and compassion, as it continually strives to address unmet medical needs with its innovative solutions. With strong leadership and a dedication to breakthrough therapies, the company stands ready to capitalize on the growing demand for specialized medications within the healthcare landscape.
See Also
What is Neurocrine Biosciences Inc's Accounts Receivables?
Accounts Receivables
481.1m
USD
Based on the financial report for Sep 30, 2024, Neurocrine Biosciences Inc's Accounts Receivables amounts to 481.1m USD.
What is Neurocrine Biosciences Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
33%
Over the last year, the Accounts Receivables growth was 15%. The average annual Accounts Receivables growth rates for Neurocrine Biosciences Inc have been 43% over the past three years , 33% over the past five years .
You don't have any saved screeners yet
